BioCryst Pharmaceuticals Inc BCRX shares are trading significantly lower Friday after the company paused enrollment in clinical trials with BCX9930 while it investigates elevated serum creatinine levels seen in some patients.
During the investigation, the company will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials. Patients currently enrolled in the trials will continue on the study drug for now.
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
See Also: Why Sunshine Biopharma Stock Is Falling Today
BCRX 52-Week Range: $9.23 - $19.99
According to data from Benzinga Pro, the stock was down 31.6% at $12.23 at time of publication.
Photo: jarmoluk from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
